Japan
SEEDSUPPLY INC. is a Japan-based startup founded in 2017 with a focus on Agriculture and Biotechnology. The company's slogan "We have the technology to identify seed compounds and target proteins that lead to first in class drug" highlights its core competency. The startup operates as a contract research organization, specializing in the identification of seed compounds that lead to first-in-class drugs.
The last investment, a Seed Round, was secured on 01 January 2018, with funding from Takeda Pharma, which aligns with the company's commitment to pharmaceutical innovation. The services offered by SEEDSUPPLY INC. include groundbreaking capabilities such as binding compounds screening, binding proteins identification, and the supply of binders for GPCRs and SLC transporters.
With a proprietary compound library of over 400K and access to a human protein library boasting greater than 18,000 proteins, the startup's technology and resources position it at the forefront of drug discovery and development. Notably, the ability to handle unexplored drug targets and identify compounds with unique profiles demonstrates the company's disruptive potential in the biotech space.
Overall, SEEDSUPPLY INC. presents a compelling investment opportunity due to its innovative approach to drug discovery, strong industry positioning, and strategic partnership with a leading pharma player like Takeda Pharma. The startup's ability to leverage cutting-edge technology and extensive libraries to drive drug development makes it an attractive prospect for venture capital investment.
